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Abstract  Surgical reconstruction of the anterior cruciate ligament (ACL) has a protracted healing phase due to poor 
osseous tissue integration at the graft/host interface. Intervention with an autologous cell-based therapy using human mes-
enchymal stem cells (hMSCs) derived from haemarthrotic fluid aspirated at the acute phase of injury has been postulated to 
accelerate healing, though until now the practicalities of this approach have not been demonstrated. hMSCs were derived by 
plastic adherence from haemarthrosis fluid aspirated from 20 patients presenting at clinic with acute knee injury. Patient 
details were recorded including age and sex of patient, injury and time between injury and aspiration. The phenotype of 
hMSCs was characterised by flow cytometry analysis of cell surface antigens. Differentiation potential was analysed by 
culturing hMSCs with different pro-differentiation stimuli to drive osteogenesis, adipogenesis and chondrogenesis. Com-
parative analysis of differentiation was made by quantitative PCR for lineage-specific gene expression and quantitative 
biochemical analyses. hMSC derivation was independent of age, sex and time between injury and aspiration however there 
was a statistically significant increase in frequency of derivation from haemarthosis samples that had been aspirated from 
bone fracture injuries compared to soft tissue injuries. hMSCs showed differential expression of cell surface antigens and 
there were also significant differences in their osteogenic, adipogenic and chondrogenic responses between samples. We have 
demonstrated the feasibility of deriving multipotent hMSCs from haemarthrosis fluid aspirated from acute knee injuries. 
Further optimisation of processing and differentiation methodologies must be achieved to develop a feasible clinical treat-
ment which accelerates ACL reconstruction. This study has identified challenges in the harvesting, bio-processing and 
characterisation of hMSCs which would be broadly applicable to the development of all autologous orthopaedic cell thera-
pies. 
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1. Introduction 
Injury and rupture of the anterior cruciate ligament (ACL) 
as a result of trauma is common and results in acute bleed-
ing into the knee joint[1]. The reconstruction of the liga-
ment requires the tethering of an autograft inside a bony 
tunnel and the successful surgical outcome of this technique 
is wholly dependent upon tissue integration and remodel-
ling to enable strong anchorage at the graft/host interface[2] 
Adult stem cells, particularly human mesenchymal stem-
cells (hMSCs), have long held significant potential for their 
application in the reconstruction and regeneration of  
 
* Corresponding author: 
rachel.oldershaw@ncl.ac.uk (Rachel A. Oldershaw) 
Published online at http://journal.sapub.org/ajscr 
Copyright © 2012 Scientific & Academic Publishing. All Rights Reserved 
orthopaedic tissues including cartilage, bone, tendon and 
meniscus[3-6]. Within the context of ACL reconstruction 
hMSCs potentially offer a new autologous therapeutic mo-
dality to accelerate tissue repair, graft integration and resto-
ration of normal knee function. Whilst commonly being 
derived from the stromal compartment of bone marrow 
hMSCs have been sourced from diverse tissues including 
adipose, trabecular bone, cartilage, skeletal muscle, periph-
eral blood and synovial fluid[7-10]. Analgesic aspiration of 
an acute knee effusion could therefore allow for harvesting 
of blood and tissue fluid with a view to isolating hMSCs[11, 
12]. This presents a practicable clinical model by which 
hMSCs are derived, expanded and assembled into an 
autologous deliverable product during the 10-12 week pe-
riod required for stabilisation of the knee joint prior to re-
constructive surgery.  
We wished to examine the feasibility of reproducibly 
2  David J. Deehan et al.:  Differential Release of Heterogeneous Human Mesenchymal  
  Stem Cell Populations from Haemarthrotic Traumatic Knee Injury 
 
harvesting and isolating hMSCs from haemarthroses and 
demonstrate their multipotential with the longer term view 
of their introduction with a scaffold to enhance tissue repair. 
We have investigated the derivation of hMSCs from a con-
secutive series of 20 patients who presented at clinic with a 
diverse range of acute knee trauma. hMSC populations 
were characterised for expression of key cell surface anti-
gens and the potential to undergo in vitro differentiation to 
chondrocytes, osteoblasts and adipocytes. We report our 
experience and outline the early difficulties encountered in 
advancing this therapeutic approach.  
2. Materials and Methods 
2.1. Acquisition of haemarthrosis fluid 
All patients gave informed consent according to Ethical 
Committee guidelines. A consecutive series of patients pre-
senting with a traumatic knee haemarthrosis underwent as-
piration under aseptic conditions. Samples were collected in 
heparinised specimen tubes and immediately stored at 4ºC. 
Samples were processed within 24 hours of aspiration. 
Clinical diagnoses as suspected through clinical examination 
were confirmed by plain radiography and MRI scanning. 
2.2. Cell Culture 
All cell culture reagents were purchased from Invitrogen, 
Paisley, UK unless otherwise stated.  
2.2.1. Derivation and culture of hMSC  
Hemarthrosis fluid was diluted with DPBS at a ratio of 1:4, 
layered onto a 12ml volume of Ficoll-Paque™ Premium (GE 
Healthcare Life Sciences, Buckinghamshire, UK) and cen-
trifuged at 600 x g for 20 minutes. The mononuclear cell 
fraction was centrifuged at 25,000 x g for 5 minutes and the 
cell pellet resuspended in hMSC medium (Minimum Essen-
tial Medium (MEM) α medium, 10%(vol/vol) FBS, 2mM 
GlutaMAX™, 5ng/ml FGF2) and seeded in a T-75 cell cul-
ture flask at a density of 300 x 105 cells / cm2. After 24 hours 
culture medium was removed and the culture area rinsed 
with DPBS. Bone marrow mononuclear cells (Lonza, 
Wokingham, UK) were seeded in a T-75 cell culture flask at 
a density of 300 x 105 cells / cm2 and cultured in hMSC 
medium as previously described[13].  
2.2.2. Osteogenic differentiation 
hMSCs were seeded cultured with osteogenic medium 
(Dulbecco’s Modified Eagles Medium (DMEM), 10% 
(vol/vol) FBS, 2mM GlutaMAX™, 10mM 
β-glycerophosphate, 10nM dexamethasone, 100nM 
L-ascorbic acid-2-phosphate). Cultures were maintained for 
4 weeks[14]. 
2.2.3. Chondrogenic differentiation 
hMSC were detached from monolayer and resuspended in 
chondrogenic medium(Dulbecco’s Modified Eagles Me-
dium (DMEM), 2mM GlutaMAX™, 100nM dexamethasone, 
100nM L-ascorbic acid-2-phosphate, 40µg/ml L-proline, 1% 
(vol/vol) ITS+1, 10ng/ml TGF-β3). Cell aggregates (5 x 105 
cells / aggregate) were formed by centrifuging the tubes at 
300 x g for 5 minutes. Cultures were maintained for 2 
weeks[13]. 
2.2.4. Adipogenic Differentiation 
Adipogeneic differentiation was initiated by cyclical 
treatment of 72 hours culture with adipogenic induction 
medium (Dulbecco’s Modified Eagles Medium (DMEM),  
10%  (vol/vol) FBS, 2mM GlutaMAX™, 1% (vol/vol) 
ITS+1, 1µM dexamethasone, 100µM indomethacin, 500µM 
3-isobuty-1-methylxanthine) followed by 24 hours culture 
with adipogenic maintenance medium (Dulbecco’s Modified 
Eagles Medium (DMEM), 10% (vol/vol) FBS, 2mM Glu-
taMAX™, 1% (vol/vol) ITS+1) . After 4 cycles cells were 
cultured for 7 days in adipogenic maintenance medium[14]. 
2.3. Flow Cytometry 
hMSC populations was analysed by flow cytometry[15]; 
primary antibodies(5µg/ml) were taken from the Human 
Multipotent Mesenchymal Stromal Cell Marker Antibody 
Panel (R&D Systems, Minneapolis, USA, secondary anti-
body (donkey anti-mouse IgG Alexa 488; 8µg/ml (Molecu-
lar Probes, Invitrogen)). Cell labelling was analysed with a 
BD FACSCanto™ II flow cytometer and BD FACSDiva™ 
software (BD, Oxford, UK). 
2.4. Gene Expression Analysis 
Total RNA was prepared from monolayer cell cultures 
using Tri-reagent. Total RNA was prepared from chondro-
genic cell aggregates using Tri-reagent in conjunction with 
the Molecular Grinding Resin™ with Pestle and Mortar kit 
(GBiosciences, St Louis,USA). Total RNA(1µg per reaction) 
was reverse transcribed using 500ng random hexamers, 
500µM dNTPs, 200U M-MLV reverse transcriptase and 1 X 
reverse transcription reaction buffer (Promega, Southampton, 
UK). Quantitative PCR(qPCR) was performed with the 
qPCR™ Core Kit for Sybr™ Green I. Each qPCR reaction 
was assembled to a total volume of 25µl using 1µl cDNA 
template, 300nM gene-specific forward and reverse primer 
set, 1 X PCR reaction buffer, 3.5mM MgCl2, 200µM dNTPs, 
0.625U HotGoldStar enzyme, 1:66000 Sybr Green I. 
Gene-specific forward and reverse primer sets were as pre-
viously published; GAPDH[16], AP2 and LIPOPROTEIN 
LIPASE[17], CBFA1 and ALKALINE PHOS-
PHATASE[18]. Data was normalised to GAPDH using the 
delta-delta method[19]. 
2.5. Histological Analysis 
2.5.1. Safranin O stain of chondrogenic cell aggregates 
Chondrogenic cell aggregates were fixed in 4% (vol/vol) 
formaldehyde, embedded in paraffin wax and sectioned 
(5µm). Deparaffinised sections were stained in Harris’ 
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haematoxylin, stained with 0.02% (wt/vol) aqueous fast 
green FCF for 3 minutes, and stained with 0.1% (wt/vol) 
aqueous safranin O for 5 minutes. Slides were mounted using 
DePeX mounting medium. 
2.5.2. Alizarin red stain of osteogenic cultures 
Osteogenic cultures were stained with Alizarin Red (2% 
wt/vol, pH4.2) for 2 hours at room temperature. Quantifica-
tion of alizarin red staining was carried out by solubilising 
cell cultures with 2% (wt/vol) SDS and measuring the ab-
sorbance (A492) using a Multiskan Ascent plate reader (MTX 
Lab Systems, Inc., Vienna, USA). 
2.6. Biochemical Analysis 
2.6.1. Preparation of Cell Lysates 
Monolayer cell cultures were lysed in 2ml volumes of  
0.01% Triton-X-100. Chondrogenic cell aggregates were 
digested in 20µl of 10U/ml of papain in papain buffer 
(100mM sodium acetate, 2.4mM EDTA, 5mM L-cysteine 
(pH5.8)) at 60°C.  
2.6.2. Quantification of DNA 
Total DNA in the prepared cell lysates was measured us-
ing the Quant-it™ PicoGreen® dsDNA Assay kit. Fluores-
cence was measured using a Fluoroskan I plate reader (MTX 
Lab Systems, Inc.). 
2.6.3. Metachromatic Quantification of Sulphated Glyco-
saminoglycans  
Quantification of sGAG was carried out by 
1,9-dimethylmethylene blue (DMMB) assay. Experimental 
samples were mixed with DMMB solution (0.16% (wt/vol) 
DMMB, 0.2% (vol/vol) formic acid, 30mM sodium formate 
(pH 3.5)) and the absorbance(A595) read using a Multiskan 
Ascent plate reader(MTX Lab Systems, Inc.). Values were 
calibrated against known concentrations of shark chondroitin 
sulphate. 
2.7. Statistical Analysis 
Two-sample Student’s T-tests were carried out on data 
sets that were seen to be normally distributed. Where data 
was not normally distributed non-parametric equivalents 
were used. 
3. Results 
3.1. Derivation of hMSC Populations from Haemarthro-
sis Fluid  
We compared the ability to derive hMSC populations 
from haemarthrosis fluid that had been aspirated from 20 
consecutive patients presenting at clinic with a diverse range 
of acute knee trauma(Table 1). The study group comprised 
 
 
11 male and 9 female patients aged between 15-79 years with 
the average age being 48 years and the median age 52 years. 
Eight of the twenty acute knee injuries were resultant of soft 
tissue ruptures where bleeding into the synovial joint space 
would occur solely from the peripheral circulation. Bone 
fractures accounted for twelve of the twenty acute knee 
injuries and as such the aspirated haemarthosis would con-
tain a further molecular and cellular contribution from the 
bone marrow compartment of the osseous tissue. For the 
majority of samples aspiration of the haemarthrosis took 
place within 1 day of injury. Five of the samples were aspi-
rated within 1 week and the remaining around 2 weeks 
(sample 3, 15 days; sample 14, 14 days) post-injury. 
We observed a significant amount of haemolysis within 
some of the samples such that we were frequently unable to 
resolve clear phase separation of the mononuclear cell 
frac tions following ficoll-gradient centrifugation. Col ony-f
orming unit fibroblasts(CFU-Fs) with characteristic hMSC 
morphology were observed between 7-14 days post-seeding 
from twelve out of twenty samples. The number of CFU-Fs 
obtained from each sample was independent of the amount 
of fluid that was aspirated. The ability to derive hMSC 
populations was independent of gender, age and time be-
tween injury and aspiration; however there was a significant 
difference between rate of derivation and the origin of hae-
marthrosis. We derived hMSC populations from 9 out of the 
12 samples that had been aspirated following bone fracture 
injuries compared to three of the eight haemarthroses arising 
from soft tissue ruptures (P<0.005). 
3.2. Human Mesenchymal Stem Cell Populations De-
rived from Aspirated Haemarthroses Display Het-
erogeneric Cell Surface Antigen Expression between 
Samples  
Populations of hMSCs that had been successfully derived 
from aspirated haemarthroses were expanded to passage 2 in 
in vitro culture and analysed by flow cytometry for the ex-
pression of characteristic hMSC cell surface antigens (Figure 
1). Data is omitted for samples 2, 8 and 12 where we were 
unable to generate sufficient cell numbers to carry out flow 
cytometry analysis alongside multipotent differentiation 
assays.  
The proportion of hMSCs expressing each of the cell 
surface antigens was highly heterogeneous between samples. 
In general, a high proportion of each cell population was 
seen to express CD44, CD90, CD105 and CD166. CD44 was 
expressed on over 94% of hMSC populations with the ex-
ception of samples 3, 1 and 17. CD90 was expressed on over 
95% of hMSC populations with the exception of samples 6, 3 
and 18. CD105 was expressed on over 95% of hMSC 
population with the exception of samples 11, 3, 17 and 6. The 
cell surface antigen CD166 was expressed on a relatively 
high proportion of cells(>80%) within hMSC populations 
derived from samples 1, 11, 17, 18 and 20. The proportion of 
cells expressing the cell surface antigens  
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Table 1.  Characterisation of haemarthosis fluid samples aspirated from 20 patients presenting at clinic with acute knee trauma. The ability to derive hMSC 
populations from each haemarthrosis is shown. Alongside we have presented the age and gender of the patient and the clinical diagnosis of the acute knee 
injury. The injuries are classified for the origin of the haemarthrosis and the time between injury and aspiration for each sample 
 
 
CD106 and CD146 were lower and also more heteroge-
neous across cell populations. 
In addition to characterising the expression of known 
hMSC cell surface antigens we carried out flow cytometry 
analysis for the cell surface antigens CD19 and CD45 (ex-
pressed on haematopoietic stem cells and their cell lineage 
derivatives but not hMSCs). There was no detectable ex-
pression of CD19 or CD45 within hMSC populations de-
rived from haemarthrosis samples 6, 11 and 17. There was a 
small proportion of hMSCs that were shown to express 
CD19 within samples 1 and 13 and CD45 within samples 16, 
18 and 20. Significantly, hMSC populations that were deri- 
 
Figure 1.  Flow cytometry analysis of hMSC populations. Human mes-
enchymal stem cell cultures that had been derived and expanded to passage 
2 were analysed for expression of a panel of cell surface antigens charac-
terised to be either present or absent on hMSCs. High numbers of cells 
expressing positive markers confirmed that we had derived hMSCs however 
the relative abundance of individual cell surface antigens varied considera-
bly revealing highly heterogenic expression between samples. The detection 
of CD19 and CD45 expressing cells within some cell populations showed 
contamination with non-hMSC cell types 
ved from samples 13 and 18 contained high proportions of 
cells that expressed CD45 and CD19 respectively. Sample 3 
was seen to be the most heterogeneous of the hMSC popu-
lations with cells expressing both CD19 (66%) and CD45 
(50%). 
3.3. Human Mesenchymal Stem Cell Populations De-
rived from Haemarthroses Exhibit Variation in 
Multipotent Differentiation between Samples 
To investigate the potential for multipotent differentiation, 
hMSC populations that had been successfully derived from 
haemarthrosis samples were expanded to passage 2 before 
being cultured in vitro with appropriate stimuli to promote 
differentiation to osteoblast, adipocyte and chondrocyte cell 
lineages[11,12].  
All twelve of the hMSC populations that had been derived 
from haemarthrosis samples underwent osteogenic differen-
tiation. At day 0 hMSCs that had been seeded at low cell 
density were seen to have a characteristic fibroblastic mor-
phology. After 28 days of osteogenic differentiation sig-
nificant cellular proliferation was evident. Cells had acquired 
an osteoblast-like cuboidal cell morphology and were en-
cased within an extensive extracellular matrix (data not 
shown). CBFA1 and ALKALINE PHOSPHATASE, key 
markers of  osteoblast phenotype, were expressed within all 
osteogenic cultures after 28 days though expression varied 
between hMSC populations by 100-fold and 1000-fold re-
spectively for each gene(Figure 2a, b). Quantification of the 
amount of DNA was carried out at day 0 and day 28 as a 
measure of the amount of cellular proliferation that occurred 
during osteogenic differentiation(Figure 2c). For the major-
ity of hMSC populations there was between 4 and 6-fold 
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increase in DNA during osteogenic differentiation, indica-
tive of cells within the culture having undergone 2-3 rounds 
of cell division. Some cell populations showed greater pro-
liferative potential with 8 and 12-fold increases in the 
amount DNA(3-4 rounds of cell division) and 20 to 30-fold 
increases(5-6 rounds of cell division).   
Histological characterisation for calcified matrix was car-
ried out by staining cell cultures with alizarin red (Figure 2d). 
Unsurprisingly at day 0 alizarin red staining was negative. In 
contrast, at day 28 there was significant alizarin red staining 
across the culture dish and this was apparent for all hae-
marthrosis-derived hMSC cultures that had between treated 
with pro-osteogenic stimuli. To provide a quantitative 
measure of matrix calcification, day 28 cultures that had 
been stained with alizarin red were solubilised and the ab-
sorbance read at A492. We have presented this as absorbance 
per amount of DNA within each sample; reflecting the con-
tribution to matrix calcification per cell (Figure 2e). For the 
majority of hMSC populations the absorbance per DNA was 
between 0.07 and 0.1 units. However, hMSC populations 
derived from haemarthrosis samples 6 and 16 and those 
derived from samples 1, 2 and 18 showed approximately 3 
and 4 times the amount of calcified matrix production per 
cell respectively. 
 
Figure 2.  Characterisation of osteogenic differentiation potential of 
hMSC populations. Human mesenchymal stem cell cultures that had been 
derived and expanded to passage 2 were analysed for their potential to 
differentiate to osteogenic, adipogenic and chondrogenic cell lineages. 
Osteogenic differentiation was assayed by gene expression analysis for (a) 
CBFA1 and (b) ALKALINE PHOSPHATASE (ALP) after 28 days in 
pro-osteogenic culture. (c) Cellular proliferation during osteogenic differ-
entiation was recorded as the fold-change in the amount of DNA between 
cultures at day 0 and day 28. (d) Matrix calcification of osteogenic cultures 
was visualised by alizarin red staining of day 0 and day 28 cultures. (e) As a 
quantitative measure of matrix calcification, day 28 cultures that had been 
stained with alizarin red were solubilised and the absorbance read at A492. 
Alizarin red was recorded as a function of the total amount of DNA within 
the culture to indicate the contribution of calcification per cell.  
All twelve of the hMSC populations that had been derived 
from haemarthrosis samples underwent adipogenic diffe-
rentiation. AP2 and LIPOPROTEIN LIPASE, key markers of 
adipogenic phenotype, were expressed within all adipogenic 
cultures after 30 days though expression varied between 
hMSC populations by up to 1000-fold for each gene (Figure 
3a-b). Cell cultures treated with pro-adipogenic stimuli be-
gan to show evidence of lipid vesicle accumulation within 
cells from cycle 3 of differentiation onwards. The number 
and size of lipid vesicles within individual cells continued to 
increase such that by the end of the differentiation period 
adipogenic cells were clearly visible across 10-20% of the 
culture area. Adipogenic cells are seen as greatly enlarged 
cells packed densely with cytoplasmic vesicles (Figure 3c). 
 
Figure 3.  Characterisation of adipogenic differentiation potential of 
hMSC populations. Adipogenic differentiation was assayed by gene ex-
pression analysis for (a) AP2 and (b) LIPOPROTEIN LIPASE (LPL) after 30 
days in pro-adipogenic culture. (c) Morphological analysis of cultures at day 
30 of adipogenic differentiation showed enlarged cells with numerous 
mature lipid vesicles distributed though the cytoplasm; scale bar = 50µm 
In contrast to osteogenic and adipogenic differentiation, 
the chondrogenic response of haemarthrosis-derived hMSCs 
was poor and we were unable to extract quantities of RNA 
required for gene expression analysis. In addition hMSCs 
derived from sample 18 did not form cell aggregates. Char-
acterisation data of chondrogenic phenotype is therefore 
presented alongside that of human bone marrow-derived 
hMSCs as a positive control. Histological evaluation of 
sGAG, a key component of cartilage matrix, was carried out 
on cell aggregates which had been cultured for 14 days in 
pro-chondrogenic medium. Cell aggregates which had been 
formed from hMSCs derived from bone marrow mononu-
clear cells stained strongly with safranin O and at higher 
magnification lacunae-bound chondrocyte-like cells were 
seen to be encased within an extensive extracellular matrix 
(Figure 4a-b). In contrast cell aggregates that had been 
formed from hMSCs derived from haemarthrosis fluid were 
more heterogeneous in their cellular organisation (Figure 4c). 
Only a small portion of the tissue stained strongly with sa-
franin O. At higher magnification (Figure 4d) lacunae-bound 
chondrocyte-like cells were seen but the remaining aggregate 
tissue had a fibroblastic phenotype which counter-stained 
with fast green.  
Biochemical analysis was carried out to measure the fold 
change in the amounts of DNA (Figure 4e) and sGAG 
(Figure 4f) within cell aggregates after 14 days of chondro-
genic differentiation. For all but three of the hMSC popula-
tions there was on average a one third decline in the amount 
of DNA measured at days 0 and day 14 and hence a loss of 
cellular content from the cell aggregates during chondro-
genic differentiation. Only one out the twelve samples that 
were assayed for chondrogenic differentiation(sample 20) 
showed a significant increase in cellular proliferation (3.2 
fold increase between days 0 and 14; P<0.05).  The accu-
mulation of sGAG during chondrogenic differentiation of 
cell aggregates was quantified by DMMB assay (Figure 4f). 
We measured increases of between 2.5 and 6-fold in the 
amount of sGAG accumulated within cell aggregates formed 
from the majority of hMSC populations(P<0.05). Cell ag-
gregates that had been formed from hMSCs derived from 
sample 20 showed the highest production of sGAG with a 
10-fold increase in the amount accumulated. There was no 
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significant increase in the amount of sGAG formed from 
hMSC populations derived from samples 1, 11, 12 and 13. 
Cell aggregates formed from hMSCs derived from bone 
marrow showed little increase in cell proliferation during the 
14 days of chondrogenic differentiation but there was over 
10-fold increase in the amount of sGAG accumulated in 
comparison to the most robust of cell aggregates derived 
from haemarthrosis fluid. 
 
Figure 4.  Charcaterisation of chondrogenic differentiation potential of 
hMSC populations. Chondrogenic differentiation was analysed by safranin 
O staining of cells aggregate sections. (a) Images at low magnification 
revealed strong safranin O staining of cell aggregates formed from hMSCs 
derived from bone marrow; scale bar = 500mm. (b) At higher magnification  
rounded chondrocyte–like cells were shown to be encased within an exten-
sive ECM; scale bar = 100µm. (c) Safranin O staining of cell aggregates 
formed from hMSCs derived from haemarthrosis fluid. Staining was weaker 
in comparison to that observed in cell aggregates formed from hMSCs 
derived from bone marrow and was also more heterogenic staining within 
the cell aggregates; scale bar = 500µm. (d) At high magnification rounded 
chondrocyte–like cells were shown to be encased within an extensive ECM; 
scale bar = 100µm. (e) Cellular proliferation during chondrogenic differen-
tiation was recorded as the fold-change in the amount of DNA between cell 
aggregates cultures at day 0 and day 14. (f) Fold-change in the amount of 
sGAG accumulated between day 0 and day 14 of chondrogenic culture was 
measured by DMMB assay. BM = bone marrow. Values represent mean 
values ± S.E.M; n=3. 
4. Discussion 
The presence of hMSC populations within synovial fluid 
is well documented and their elevated numbers in response 
to disease and trauma demonstrates a role in the repair of 
damaged tissues within the synovial joint[8, 9, 20-22]. Our 
aim in this study was to investigate the potential of these 
cells as an autologous cell-based therapeutic modality. It has 
been argued that such cells may play a role in accelerating 
graft integration at time of surgical reconstruction[20-23]. 
This study accurately defines the potential yield, identifies 
the limitations in such work and begins to characterise the 
behaviour of such cells in relation to clinical characteristics. 
Only until such work is complete can this new technology 
become clinically and commercially deliverable. 
In this study hMSC populations were derived from 60% of 
haemathrosis aspirates that were collected from clinic. 
Derivation of hMSCs was independent of gender, time from 
injury to aspiration or the nature of the intra-articular event. 
Previous studies have found that hMSC derivation and cul-
ture is dependent on age[24, 25]. However, although we 
were unable to derive cells from the three most elderly pa-
tients, we were able to successfully obtain MSC populations 
from haemarthrosis fluid which had been aspirated from 
patients up to 66 years of age.  
The greatest influence on the ability to derive hMSCs was 
the origin of the haemarthrosis. We were significantly more 
successful at deriving hMSC populations from hae-
marthroses arising from bone fractures where there would 
have been an additional cellular component from the bone 
marrow compartment. From our observations and handling 
of the haemarthrosis samples, we would consider that the 
quality of the aspirate also influenced the ability to derive 
hMSCs. Despite patients being administered with heparin 
upon presentation at the clinic and also collection of the 
aspirate into heparin containing collection tubes there was a 
significant frequency of blood clotting and haemolysis be-
tween the aspiration and processing of the sample. This 
haemolysis appeared to compromise the ability to obtain 
clear phase separation from Ficoll-gradient centrifugation 
and resulted in contamination of the mononuclear cell 
population. We conjecture that this may have been a con-
tributing factor in our inability to derive hMSCs from some 
heamarthrosis samples and will preclude the derivation of 
adequate cells for the generation of clinically deliverable 
product. Further understanding of the bio-processing pro-
cedures involved, such as aspiration technique, initial tissue 
handling and optimisation of the conditions used to store and 
transport the haemarthrosis fluid should reduce the fre-
quency of haemolysis.  
We specifically characterised hMSC populations at pas-
sage 2 since we consider this to be the most appropriate point 
at which the cells would be used clinically. Using hMSCs at 
low passage should reduce the risk of deleterious effects 
brought about by adaptation to in vitro culture[26] whilst 
permitting the amplification of significant cell numbers for 
generating the clinical deliverable and use in mandatory 
testing as required by the appropriate regulatory agencies 
(Eudralex, Volume 4, Annex 2).  
Flow cytometry was carried out using a panel of com-
mercially available antibodies specific for cell surface anti-
gens expressed on hMSCs[6]. Differential expression of 
each antigen demonstrated that we derived highly hetero-
geneous populations; it is likely that these would become 
more homogeneous with prolonged culture[27, 28]. Whilst 
most antigens are expressed within high proportions of each 
cell population (CD44, CD90, CD105 and CD166) we noted 
  American Journal of Stem Cell Research 2012, 1(1): 1-8 7 
 
 
much lower and more heterogeneous expression between 
cell populations when analysing expression of CD106 and 
CD146. Flow cytometry analysis will be one method by 
which we would carry out the necessary validation of cul-
tured hMSC populations prior to clinical application. This 
data suggests that we will need to undertake a more consid-
ered approach in identifying a panel of appropriate antigens 
that will give us reliable characterisation of the hMSC phe-
notype with the minimum number of cells.  
  In some samples there were large numbers of cells ex-
pressing the non-mesenchymal antigens, CD19 and CD45. It 
is likely that these cells would be lost during continued cul-
ture expansion though having argued strongly for the clinical 
application of these cells at low passage their exclusion from 
the final cell therapy must be addressed. We believe reduc-
tion of haemolysis will enable the isolation of cleaner 
mononuclear cell fractions and reduce lymphocyte con-
tamination. It may be possible to introduce a negative selec-
tion technique to remove contaminating cells prior to in-
corporating the hMSCs onto the selected scaffold[29]. 
Gene expression and biochemical analyses showed that 
we derived multipotent hMSC cells though there was a var-
ied response to differentiation stimuli between cell popula-
tions. All of the twelve hMSC populations derived under-
went adipogenic and osteogenic differentiation though some 
populations had a more robust proliferative and/or differen-
tiation response than others. It is possible that for some 
samples(for instance sample 3) in which there were con-
taminating CD19+, CD45+ lymphocyte populations the cells 
had a more pro-inflammatory phenotype resulting in more 
proliferation over differentiation. Whilst there was evidence 
of chondrogenic differentiation within cell aggregates only 
one of the twelve hMSC populations showed true potential to 
differentiate along this lineage. Previous evidence has shown 
that the potential for differentiation toward cell lineages is 
restricted by tissue from which hMSCs are derived[30, 31]. 
For our intended aim of improved integration of the 
graft/host interface following ACL reconstruction, poor 
chondrogenic and adipogenic differentiation of our isolated 
hMSCs is not a concern. However, a more standardised 
response to osteogenic stimuli between different hMSC 
populations will need to be optimised. We predict improved 
global differentiation when the amount of non-hMSC cells 
has been reduced from starting cultures though the greatest 
benefit will be achieved through modification of 
pro-osteogenic culture conditions with particular emphasis 
on the microenvironment presented by the scaffold. 
5. Conclusions 
We have demonstrated the feasibility of deriving hMSC 
populations from haemarthrotic fluid that has been aspirated 
in the acute clinical setting. Whilst clinical and scientific 
challenges remain we believe that these cells could fulfil a 
potential role in modulating the healing response to acute 
intra-articular injury. 
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